You are here:
Darzalex
Smouldering multipel myeloom.
No judgement
9,488,224.50
Clinical trials
Daratumumab
Oncology and Hematology
Indication extension
Multiple Myeloma
Janssen
Other, see general comments
Subcutaneous
Injection
Intermural (MSZ)
Centralised (EMA)
2021
April 2022
Fabrikant verwacht registratie in het tweede kwartaal van 2022.
1800mg
NCT03301220.
Jaar 1: 23 toedieningen; jaar 2 en 3: 13 toedieningen. Maximale behandelduur van 36 maanden.
< 111
Market share is generally not included unless otherwise stated.
Pakketadvies daratumumab.
Jaarlijks aantal nieuwe multipel myeloma patiënten bedraagt 1.117, waarvan 10% asymptomatisch: 111.
61,735.00 - 109,224.00
Fabrikant.
Jaar 1: €109.224; Jaar 2 & 3: €61.735. Op basis van de lijstprijs.
This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year.
There is currently nothing known about off label use.
There is currently nothing known about indication extensions.
There is currently no futher information available.
Understanding of expected market entry of innovative medicines